TY - JOUR
T1 - Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation
T2 - QOL in Elderly Patients with AF
AU - Miura, Kotaro
AU - Ikemura, Nobuhiro
AU - Kimura, Takehiro
AU - Katsumata, Yoshinori
AU - Ueda, Ikuko
AU - Tanimoto, Kojiro
AU - Ohki, Takahiro
AU - Shinmura, Daisuke
AU - Negishi, Koji
AU - Fukuda, Keiichi
AU - Takatsuki, Seiji
AU - Kohsaka, Shun
N1 - Funding Information:
This study was funded by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Grant no. 16H05215, 16KK0186) and by an unrestricted research grant from Bayer Yakuhin Ltd.
Funding Information:
We would like to thank all the study coordinators, investigators, and patients who participated in the Keio Interhospital Cardiovascular Studies for Atrial Fibrillation registry. The site investigators were Yukihiko Momiyama, Munehisa Sakamoto, Jun Fuse, Kojiro Tanimoto, Yoko Tanimoto, Yukinori Ikegami, and Kohei Inagawa (National Hospital Organization Tokyo Medical Center); Iwao Nakamura, Jyunji Suzuki, Tomohiro Matsuhashi, and Hiroshi Shiga (Hino Municipal Hospital); Seiji Takatsuki, Yoshiyasu Aizawa, Nobuhiro Nishiyama, Takahiko Nishiyama, Yoshinori Katsumata, Shin Kashimura, Akira Kunitomi, Kazuaki Nakajima, and Taishi Fujisawa (Keio University School of Medicine); Masahiro Suzuki, Takaharu Katayama, Keisuke Matsumura, Tomohiko Ono, Hanako Tokuda, Ryutaro Yamaguchi, and Hiroaki Tanaka (National Hospital Organization Saitama National Hospital); Shigetaka Noma, Takashi Yagi, Kenichiro Shimoji, Koji Ueno, and Satoshi Mogi (Saiseikai Utsunomiya Hospital); Takashi Koyama, Shiro Ishikawa, Hideaki Kanki, Takashi Akima, Masahito Munakata, and Kazutaka Miyamoto (Saitama City Hospital); Hideo Mitamura, Kazunori Moritani, Masaru Shibata, and Toshimi Kageyama (Tachikawa Hospital); Takahiro Oki, Akiyasu Baba, Yoshinori Mano, and Hiroaki Sukegawa (Tokyo Dental College Ichikawa General Hospital); Kouji Negishi, Takahiro Koura, Daisuke Shinmura, Kotaro Fukumoto, and Hiroyuki Yamakawa (Yokohama Municipal Citizen's Hospital); Keiichi Nagami, Kazuhiro Oyamada, Kotaro Naitou, and Keijiro Chiba (Keiyu Hospital); Megumi Shimada (Tokai University Oiso Hospital); and Makoto Akaishi (Tokai University Tokyo Hospital). The clinical coordinators were Aki Kato, Ikumi Koishi, Miho Matsuoka, Takako Nozaki, Hiroaki Nagayama, Chieko Tamura, Reiko Tamura, Junko Susa, Miho Umemura, and Itsuka Saito. We are grateful to all study coordinators, investigators, and patients who participated in the Keio Interhospital Cardiovascular Studies-Atrial Fibrillation (KiCS-AF) registry. None of the additional contributors received compensation. This study was funded by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Grant no. 16H05215, 16KK0186) and by an unrestricted research grant from Bayer Yakuhin Ltd. Dr. Kohsaka received an unrestricted research grant for the Department of Cardiology at Keio University School of Medicine from Bayer Pharmaceutical and Daiichi Sankyo; grants from Bayer Yakuhin Ltd. and Daiichi Sankyo; and personal fees from Bristol-Myers Squibb. Dr. Kimura received grants from Bayer Yakuhin Ltd. Dr. Takatsuki received grants and personal fees from Bayer and personal fees from Daiichi Sankyo and Bristol-Myers Squibb. The authors report no other relationships that could be construed as a conflict of interest.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/4
Y1 - 2020/4
N2 - Background: Rhythm-control strategy, including catheter ablation (CA) application, constitutes an integral part of atrial fibrillation (AF) management. However, elderly patients are underrepresented in clinical trials, and reports on patient-reported outcome of various rhythm-control treatments remain limited. Therefore, we aimed to investigate the application of a rhythm-control strategy for elderly patients with AF. Methods: Using a prospective, multicenter Japanese registry, we analyzed 733 patients with AF aged ≥70 years who completed the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire at baseline and 1-year visit. Improvement in patient-reported quality-of-life (QOL) was assessed according to their initial treatment strategy. Results: A total of 321 patients (43.8%) were managed with rhythm-control strategy, of which 125 (17.1%) received treatment with antiarrhythmic drugs (AADs) alone and 196 (26.7%) underwent CA. Compared with the rate-control group, the rhythm-control group was younger and less likely to have comorbid conditions but had lower baseline AFEQT-overall summary (OS) scores (71.8 [standard deviation 20.3] vs. 80.0 [standard deviation 16.1]; P < .001). After the first year, AFEQT-OS scores improved regardless of treatment strategies (ie, rate- or rhythm-control). After adjusting for confounders, CA implementation and a lower baseline AFEQT score were associated with meaningful improvement in QOL (changes in AFEQT-OS score ≥5). QOL improvement among subgroups of rhythm-control patients with AADs alone was not clinically meaningful. Conclusions: In contemporary Japanese clinical practice, rhythm-control strategy is widely implemented in elderly patients with AF, and CA use is associated with improvement in QOL in carefully selected patients.
AB - Background: Rhythm-control strategy, including catheter ablation (CA) application, constitutes an integral part of atrial fibrillation (AF) management. However, elderly patients are underrepresented in clinical trials, and reports on patient-reported outcome of various rhythm-control treatments remain limited. Therefore, we aimed to investigate the application of a rhythm-control strategy for elderly patients with AF. Methods: Using a prospective, multicenter Japanese registry, we analyzed 733 patients with AF aged ≥70 years who completed the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire at baseline and 1-year visit. Improvement in patient-reported quality-of-life (QOL) was assessed according to their initial treatment strategy. Results: A total of 321 patients (43.8%) were managed with rhythm-control strategy, of which 125 (17.1%) received treatment with antiarrhythmic drugs (AADs) alone and 196 (26.7%) underwent CA. Compared with the rate-control group, the rhythm-control group was younger and less likely to have comorbid conditions but had lower baseline AFEQT-overall summary (OS) scores (71.8 [standard deviation 20.3] vs. 80.0 [standard deviation 16.1]; P < .001). After the first year, AFEQT-OS scores improved regardless of treatment strategies (ie, rate- or rhythm-control). After adjusting for confounders, CA implementation and a lower baseline AFEQT score were associated with meaningful improvement in QOL (changes in AFEQT-OS score ≥5). QOL improvement among subgroups of rhythm-control patients with AADs alone was not clinically meaningful. Conclusions: In contemporary Japanese clinical practice, rhythm-control strategy is widely implemented in elderly patients with AF, and CA use is associated with improvement in QOL in carefully selected patients.
UR - http://www.scopus.com/inward/record.url?scp=85078740081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078740081&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2020.01.011
DO - 10.1016/j.ahj.2020.01.011
M3 - Article
C2 - 32028139
AN - SCOPUS:85078740081
SN - 0002-8703
VL - 222
SP - 83
EP - 92
JO - American Heart Journal
JF - American Heart Journal
ER -